Multimodal management of surgery- and radiation-refractory meningiomas: an analysis of the French national tumor board meeting on meningiomas cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Le Van Tuan, Graillon Thomas, Jacob Julian, Vauleon Elodie, Feuvret Loic, Boch Anne-Laure, Boetto Julien, Boone Mathieu, Bronnimann Charlotte, Caire François, De Barros Amaury, Delaitre Mariette, Di Stefano Anna Luisa, Dore Mélanie, Ducray François, Dufour Christelle, Engelhardt Julien, Fontaine Denys, Froelich Sebastien, Helleringer Matthieu, Huchet Aymeri, Joncour Anthony, Jouanneau Emmanuel, Mallereau Charles-Henry, Monfilliette Apolline, Le Fur Emmanuelle, Zemmoura Ilyess, Chinot Olivier, Sanson Marc, Kalamarides Michel, Loiseau Hugues, Peyre Matthieu
Аннотация
METHODS: We retrospectively reviewed the charts of patients presented to the multidisciplinary Meeting between 2016 and 2019. We selected patients with a progressive disease after at least two treatments, including surgery and radiotherapy.
RESULTS: In this multicentric cohort of 86 cases, patients harbored 17 (19.8%) WHO Grade I, 48 (55.8%) WHO Grade II and 21 (24.4%) WHO Grade III tumors. The median number of treatments received before inclusion was 3 (range: 2 - 11). Following the Board Meeting, 32 patients (37.2%) received chemotherapy, 11 (12.8%) surgery, 17 (19.8%) radiotherapy, 14 (16.3%) watchful observation and 12 (13.9%) palliative care. After a mean follow-up of 13 months post-inclusion, 32 patients (37.2%) had died from their disease. The mean progression free survival was 27 months after radiotherapy, 10 months after surgery, 8.5 months after chemotherapy (Bevacizumab: 9 months - Octreotide/Everolimus: 8 months).
CONCLUSIONS: Surgery- and radiation-refractory meningiomas represent a heterogeneous group of tumors with a majority of WHO Grade II cases. If re-irradiation and redo-surgery are not possible, bevacizumab and octreotide-everolimus appear as a valuable option in heavily pre-treated patients considering the current EANO guidelines.